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Abstract We have investigated the effect of the flavonoid
derivative LY 294002, a potent and selective phosphatidylinositol
3-kinase inhibitor, on cell cycle progression in human choroidal
melanoma cells. We demonstrate that LY 294002 induces a
specific G1 block in asynchronously growing cells leading to an
almost complete inhibition of cell proliferation after three days of
treatment. When melanoma cells are released from a nocodazole-
induced G2/M block, LY 294002 is shown to delay and greatly
restrain the G1/S transition. The inhibitor is able to exert its
action as long as it is added during the G1 progression and before
the cells enter in S phase. We report that the LY 294002-induced
G1 arrest is closely correlated to inhibition of CDK4 and CDK2
activities leading to the impairment of pRb phosphorylation
which normally occurs during G1 progression. While the
inhibition of CDK4 may be attributed at least in part to the
decline in CDK4 protein level, CDK2 activity reduction is rather
due to the up-regulation of the CDK inhibitor p27Kip1 and to its
increased association to CDK2.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Flavonoids and their derivatives have been shown to inhibit
the proliferation of several human cancer cell lines including
breast, leukemic, ovarian and gastro-intestinal tumor cells by
arresting cell cycle progression at speci¢c stages [1]. While the
£avone quercetin has been reported to induce a G1 phase
block [2,3], the iso£avone genistein has been shown to arrest
cells at the G2/M boundary [4]. The synthetic quercetin de-
rivative L86-8275 appears to cause both G1/S and G2/M
blocks [5]. The molecular mechanisms underlying such cell
cycle arrests have not been elucidated until now, although
£avonoids have been described to inhibit several serine/threo-
nine or tyrosine protein kinases as well as lipid kinases in-
volved in signal transduction [6]. Recently, a quercetin syn-
thetic derivative called LY 294002 has been demonstrated as a
potent and selective inhibitor of PI 3-kinases [7], a family of
enzymes very likely involved in growth factor receptor signal-
ling and cell transformation [8,9]. The agonist-dependent PI 3-
kinase activation leads to rapid and transient production of
phosphoinositides PI 3,4 P2 and PI 3,4,5 P3 which have been
proposed to act as second messengers [10]. However, the sub-
sequent events responsible for the induced mitogenic response
are still poorly understood. Finally, the PI 3-kinase p110 sub-
unit has been recently proposed to have also serine/threonine
protein kinase activity [11,12]. The function of such activity
remains to be documented [13,14].
Progression of eukaryotic cells through the cell cycle is
orchestrated by sequential activation and inactivation of a
series of serine/threonine kinases, the cyclin-dependent kinases
(CDKs) associated with their respective cyclin subunits [15^
17]. G1 phase progression and G1/S transition are believed to
be regulated by CDK4 (and CDK6) which assemble with
cyclins D in mid-G1 and CDK2 which combines later with
cyclin E. CDK activity is counterbalanced by association with
low molecular weight CDK inhibitors (CKIs) [18,19]. p21Cip1
and p27Kip1 proteins belong to the ¢rst family of CKIs and
have a broad speci¢city, acting on the di¡erent G1 CDK
cyclins as well as on the S phase CDK2-cyclin A complexes.
The second and unrelated family of CKIs includes p16INK4A
and p15INK4B proteins which speci¢cally inhibit CDK4 and
CDK6. Finally, CDK activity is regulated by a complex set
of phosphorylation/dephosphorylation reactions [15^17].
Several inhibitors of G1 phase progression including TGFL
[20,21], cyclic AMP [22], rapamycine [23,24] or Q radiations
[25] have been shown to interact with the CDK regulatory
network, exerting e¡ects at both the levels and activities of
CDK-cyclin complexes. CKIs have been shown to play an
essential role in the G1 phase arrest. For example, the immu-
nosuppressant rapamycine has been shown to maintain a high
level of p27 in T-cell [26] or macrophages [22] which is mainly
responsible of the induced G1 phase block. Interestingly, ra-
pamycine has been shown to act by interfering with the
FRAP/RAFT-1/mTOR protein [27,28] which exhibits distant
homology with PI 3-kinases [13,14].
In this paper, we investigated the e¡ect of the £avonoid
derivative LY 294002 on cell cycle and proliferation in human
choroidal melanoma cells. We report that the PI 3-kinase
inhibitor induces a speci¢c G1 phase arrest correlated to up-
regulation of the CDK inhibitor p27 and inhibition of CDK4
and CDK2 activities.
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2. Materials and methods
2.1. Cell culture
Human choroidal melanoma cells (spindle-shape OCM-1 cell line)
were maintained at 37‡C in RPMI-1640 medium, pH 7.3, supple-
mented with 100 UI/ml penicillin, 100 Wg/ml streptomycin, 2.5 Wg/ml
amphotericin B, 2 mM L-glutamine and 5% FCS in humidi¢ed 5%
CO2, 95% air. All culture reagents were from Gibco. Culture media
were changed every 2^3 days. When they reached con£uence, cells
were dissociated by 0.05% trypsin-0.02% EDTA and replated at
1:30 dilution.
2.2. Cell proliferation studies
For cell growth measurement, melanoma cells were seeded at an
initial density of 3U104 cells per 35-mm dish. Indicated concen-
trations of LY 294002 (purchased from Biomol Research Laborato-
ries) were added at day 0 and 2. Control dishes received the same
volume of the solvent DMSO. Cells were harvested with trypsin-
EDTA and cell number was determined by using a Coulter Counter
(Coultronics).
2.3. Cell cycle progression analysis
Melanoma cells were plated at a density of 2U105 cells per 100-mm
dish in the absence or presence of 20 WM LY 294002. After one or
two days, cells were harvested by brief trypsinisation and centrifuged
at 500Ug for 5 min. The cell pellet was washed twice in PBS, labelled
with propidium iodide and the cell cycle distribution was determined
by £ow cytometry analysis using a Coulter Elite.
In order to synchronize cells in G2/M phase, 100 ng/ml nocodazole
was added to the culture media for 14^16 h. The detached cells were
centrifuged at 500Ug for 5 min, washed twice with PBS and then
replated in FCS medium without or with 20 WM LY 294002. Cells
were collected at the indicated times and the cell cycle distribution was
analyzed by £ow cytometry. Concurrently, total cell extracts were
prepared by direct lysis of cells either in Laemmli sample bu¡er or
in modi¢ed RIPA bu¡er (see below).
2.4. Immunoblotting and immunoprecipitation
Proteins were separated by electrophoresis on 7.5% or 10% SDS/
PAGE. Gels were either stained with Coomassie blue to control for
balanced loading or electroblotted to nitrocellulose membranes (BA85
from Cera-Labo) for 1 h at 20 V using a semi-dry transfer apparatus.
Immunoblots were developed by using the ECL detection system
(Amersham) according to the manufacturer’s instructions. Anti-
CDK4 (C-22), anti-CDK2 (M2), anti-cyclin A (BF 683) and anti-
p27 (C-19) antibodies were from Santa Cruz Biotechnology. Anti-
pRb (G3-245) was from Pharmingen.
For immunoprecipitation experiments, cells were lysed in modi¢ed
RIPA bu¡er containing 50 mM HEPES, pH 7.3, 150 mM NaCl, 1 mM
EDTA, 2.5 mM EGTA, 1 mM DTT, 1 mM sodium £uoride, 10% L-
glycerophosphate, 0.1 mM sodium orthovanadate, 10 Wg/ml aprotinin,
10 Wg/ml leupeptin, 0.1 mM PMSF, 0.1% Tween 20 and 10% glycerol.
The lysates were clari¢ed by centrifugation at 12 000Ug for 5 min at
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Fig. 1. E¡ect of LY 294002 on cell cycle progression and cell proliferation of asynchronous melanoma cells. Asynchronous melanoma cells
were cultured for the indicated times in the absence (3LY) or presence (+LY) of 20 WM LY 294002 (A, B), or for 3 days in the absence (con-
trol) or presence of increasing concentrations of the drug (C). Cell number was evaluated by counting (A, C) and results are the means of trip-
licate measurements performed on separate dishes (cell number variation below 10%). In C, data are expressed as percent of cell number in the
absence of LY 294002 (control). Alternatively, cell cycle distribution was analyzed by £ow cytometry (B) after 24 h (a, b) or 48 h (c^f) of cul-
ture without (a, c) or with (b, d, f) the drug. In e, LY 294002 was washed out from the culture after 24 h and cells were cultured for the next
24 h in the absence of the drug. In f, LY 294002 was added twice, at time 0 and after 24 h of culture. Results are, as in A and C, from one
experiment representative of three di¡erent experiments.
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4‡C and the protein contents were estimated by electrophoresis on
SDS-PAGE and Coomassie blue staining. Immunoprecipitations
were performed using the same amount of proteins (1.5 mg) for the
di¡erent samples. Antibodies previously bound to protein A-Sephar-
ose CL-4B beads (Pharmacia) were added to the cell lysates for 12 h
at 4‡C with gentle agitation. Immune complexes were collected by
centrifugation and washed three times in RIPA bu¡er, twice in PBS
and twice in kinase assay bu¡er (25 mM HEPES, pH 7.5, 10 mM
MgCl2, 1 mM DTT). After kinase assays (see below), the samples
were fractionated on SDS-PAGE and gels were electroblotted. Anal-
ysis of CDKs or associated CKIs was carried out by immunoblotting
using speci¢c antibodies.
2.5. Protein kinase assays
Kinase reactions (total volume 20 Wl) were performed for 10 min at
30‡C in 25 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM DTT, 5 Wci [Q-
32P]ATP (Amersham) with 50 WM ATP (CDK4) or 200 WM ATP
(CDK2). Two Wg of histone H1 (Boehringer-Mannheim) or 2 Wg of
pRb (QED Bioscience Inc.) were added into the respective CDK2 and
CDK4 assays. The reactions were stopped by adding 12 Wl of
4ULaemmli sample bu¡er and heated for 45 min at 30‡C. Phospho-
rylation of the substrates was analyzed by SDS-PAGE and autora-
diography of the electroblotted gel.
3. Results
3.1. Inhibition of asynchronous melanoma cell proliferation
by LY 294002
We investigated the e¡ect of the PI 3-kinase inhibitor LY
294002 on cell proliferation of choroidal melanoma OCM-1
cells. As shown on Fig. 1A, the £avonoid derivative markedly
decreased the proliferation rate of asynchronously growing
OCM-1 cells leading to an almost complete inhibition of cell
proliferation after three days of treatment. Flow cytometric
analysis demonstrated that this growth inhibitory action was
the consequence of a speci¢c G1 phase arrest (Fig. 1B). How-
ever, a signi¢cant proportion of melanoma cells escape the
block at day 1, agreeing with the fact that complete inhibition
of cell proliferation requires several days of treatment. The
e¡ect of LY 294002 was reversible since after removal of
the drug, arrested cells reentered the cycle as assessed by
£ow cytometric analysis (Fig. 1B, panel e). Fig. 1B also evi-
dences that a stronger e¡ect of LY 294002 was obtained when
the drug was added twice during a 2-day treatment (panel f),
very likely re£ecting the instability of the £avonoid derivative
in the cell. As shown on Fig. 1C, the IC50 observed for cell
proliferation inhibition was about 10 WM, a concentration
higher than, but compatible with, the one (1.4 WM) reported
for in vitro inhibition of PI 3-kinase activity [7].
3.2. Induction by LY 294002 of a mid-late G1 phase arrest
in synchronized melanoma cells
To further study the LY 294002-induced G1 phase arrest,
melanoma cells were previously synchronized in G2/M by
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Fig. 2. E¡ect of LY 294002 on cell cycle distribution of melanoma cells released from a nocodazole-induced G2/M block. Melanoma cells were
synchronized in G2/M phase by previous treatment for 14^16 h with 100 ng/ml nocodazole. Cells were then released from this block by serum
stimulation in the absence (A) or presence (B) of 20 WM LY 294002. Flow cytometry analysis was performed at the indicated times. S phase
entry was further evaluated by blotting, in parallel, cell lysates with an anti-cyclin A antibody (inserts: each lane corresponds to each time
point). Alternatively, 20 WM LY 294002 was added at various times after the nocodazole block release (C). Cell cycle distribution was analyzed
14 h after the release and the number of cells in S phase following LY 294002 treatment expressed as percent of cells in S phase after 14 h of
serum stimulation in the absence of the drug.
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a nocodazole treatment and then released from this block
by serum stimulation in the absence (Fig. 2A) or in the pres-
ence (Fig. 2B) of LY 294002. Flow cytometric analysis
shows that the PI 3-kinase inhibitor delayed (by 2^4 h)
and markedly restrained (by 40^50%) the G1/S transition.
This result was con¢rmed when cyclin A expression was
evaluated as a marker of S phase entry (Fig. 2A and B, in-
serts).
We then attempted to determine how long an exposure to
LY 294002 was required to induce the G1 phase arrest. This
was done by adding the £avonoid derivative at various times
after the nocodazole block release. Fig. 2C shows that the PI
3-kinase inhibitor was e¡ective to prevent cells from entering
S phase when added until 5 h after the release. Drug addition
at a later time (7 h) maintained fewer cells in G1 phase and,
once cells neared the G1/S transition (9^10 h), LY 294002 was
ine¡ective in preventing S phase entry.
3.3. Up-regulation by LY 294002 of the CDK inhibitor p27 and
inhibition of CDK4 and CDK2 activities
To understand the molecular events involved in the £avo-
noid derivative action on cell cycle progression, we investi-
gated the e¡ect of the compound on G1 CDK levels and
activities along the course of G1 progression in nocodazole
synchronized melanoma cells.
As shown on Fig. 3, LY 294002 did not signi¢cantly a¡ect
the CDK2 protein level. By contrast, CDK4 level decreased as
a function of the drug exposure period, with a signi¢cant
higher e¡ect after 10^14 h of treatment. As a main feature,
the CDK inhibitor p27 was shown rapidly up-regulated by the
PI 3-kinase inhibitor.
Fig. 4 shows that the CDK4 and CDK2 kinase activities
were markedly reduced in the LY 294002-treated cells as as-
sessed by enzymatic assays of speci¢c immunoprecipitates.
These declines were not the consequence of a direct inhibition
of the kinases as neither CDK4 nor CDK2 activity was af-
fected when the drug was added directly to immunoprecipi-
tates from untreated cells (not shown). CDK2 activity reduc-
tion was rather due to an increase of the ratio of p27
associated to the kinase (Fig. 4A). As we were unable to
detect any variation of p27 or p21 associated to CDK4 and
because p15 is very likely absent in melanoma OCM-1 cells
(unpublished results), the CDK4 kinase activity inhibition
(Fig. 4B) was probably due to the decrease of the protein
level. In any case, the CDK4 and CDK2 kinase reductions
were observed at early points after release from nocodazole
block, suggesting their involvement in the G1 arrest caused by
LY 294002. Noteworthy, the PI 3-kinase inhibitor markedly
reduced the pRb phosphorylation which normally occurs dur-
ing the G1 progression (Fig. 4C).
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Fig. 3. E¡ect of LY 294002 on CDK2, CDK4 and p27 levels. G2/M synchronized melanoma cells were stimulated by serum for the indicated
times in the absence (3LY) or presence (+LY) of 20 WM LY 294002. Respective cell extracts were fractionated by SDS-PAGE and the levels
of CDK2 (A), CDK4 (B) and p27 (C) were evaluated by blotting with speci¢c antibodies. Quantitative evaluations of immunoblots were per-
formed using the Biorad Gel Doc video system.
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4. Discussion
Flavonoid compounds have been reported to inhibit cell
proliferation by inducing speci¢c blocks either at the G1/S
or G2/M boundaries [1^4]. In this paper, we demonstrate
that the quercetin derivative LY 294002 causes a speci¢c G1
phase arrest in human choroidal melanoma cells. This result
agrees with a recent report showing that the drug inhibited the
proliferation of smooth muscle cells in cultured rabbit aortic
segments [7]. We report that, in human melanoma cells, the
£avonoid derivative exerts its action by inhibiting the G1
CDK activities and the subsequent phosphorylation of the
retinoblastoma protein pRb. These inhibitory e¡ects are, at
least in part, due to an induced up-regulation of the CDK
inhibitor p27. This latter result is likely not restricted to tumor
cells as a similar ¢nding has been recently reported in NIH
3T3 ¢broblasts where LY 294002 has been shown to prevent
the down-regulation of p27 induced by EGF or phorbol-
12,13-dibutyrate and to inhibit the DNA synthesis [29].
LY 294002 has been shown to be a potent inhibitor of PI 3-
kinase activity, acting as a competitive inhibitor for ATP
binding site of the enzyme [7]. This e¡ect was highly speci¢c
as other lipid kinases as well as a series of serine/threonine
kinases (including PKC, MAP kinase and S6 kinase) or tyro-
sine kinases (including EGF receptor and c-src tyrosine kin-
ases) were not a¡ected by the compound. In agreement with
this selectivity, we ¢nd that the £avonoid derivative does not
directly inhibit the CDK activities. By contrast, other £avo-
noids have been shown to inhibit several classes of protein or
lipid kinases [6]. For example, quercetin inhibits PKC, recep-
tor and non-receptor tyrosine kinases as well as PI 3- and PI
4-kinases while genistein a¡ects the activity of several tyrosine
kinases. Interestingly, the £avonoid L86-8275 has been shown
to directly inhibit cdc2 kinase activity [5]. All these observa-
tions suggest that LY 294002 exerts its e¡ects in a much more
speci¢c way than the £avonoid compounds studied until now.
However, several types of PI 3-kinases have been identi¢ed so
far. The most characterized group are heterodimers composed
of a p85 regulatory subunit and a p110 catalytic subunit [30].
In contrast, the recently cloned PI 3-kinase p110Q does not
complex to p85 and is activated by GLQ subunits [31]. A third
group of PI 3-kinases includes the human homolog of Vps34
gene product from Sacharomyces cerevisiae [32]. Whether LY
294002 inhibits identically all these PI 3-kinase species re-
mains to be determined.
In fact, the implication of PI 3-kinases in mitogenesis has
been really demonstrated with regard to the p85-p110 dimeric
enzyme only. Most convincing was the report that inhibitory
antibodies to the p110 subunit blocked the DNA synthesis
occurring in response to PDGF and EGF [33].
In any case, whether the LY 294002 action on cell cycle
regulation that we report here is only targeted by inhibition
of PI 3-kinase is questionable. Indeed, PI 3-kinases have been
recently shown to be distant homologs of two others classes of
proteins, the FRAP/RAFT-1/mTOR protein which is believed
to be a serine/threonine kinase, and a family of proteins in-
volved in DNA repair including the double-stranded DNA-
dependent protein kinase [13,14]. One cannot exclude at the
present that LY 294002 may inhibit the activity of other mem-
bers of this superfamily of proteins. In agreement with such a
speculation, wortmannin, another speci¢c inhibitor of PI 3-
kinase, has been shown to inhibit the DNA-dependent protein
kinase, even though the IC50 for this inhibition is two orders
of magnitude higher than for PI 3-kinase. By contrast, wort-
mannin does not inhibit FRAP which has been demonstrated
involved in rapamycine-induced cell cycle regulation [13].
Altogether, our results bring important light on the e¡ect of
the £avonoid derivative LY 294002 on the cell cycle machin-
ery. Further, they give insight on a possible link between PI 3-
kinase activation pathway and cell cycle regulation.
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